Sage Therapeutics Inc. (NASDAQ:SAGE)’s share price traded up 2.2% during trading on Monday . The stock traded as high as $37.33 and last traded at $37.27, with a volume of 482,476 shares changing hands. The stock had previously closed at $36.45.

Several equities analysts have commented on the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $110.00 price target on shares of Sage Therapeutics in a report on Sunday, May 8th. Leerink Swann reaffirmed a “buy” rating and issued a $66.00 price target on shares of Sage Therapeutics in a report on Tuesday, July 12th. Cowen and Company reaffirmed a “buy” rating on shares of Sage Therapeutics in a report on Tuesday, July 12th. BMO Capital Markets reaffirmed a “buy” rating on shares of Sage Therapeutics in a report on Tuesday, July 12th. Finally, Chardan Capital assumed coverage on Sage Therapeutics in a report on Tuesday, May 24th. They issued a “sell” rating and a $18.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $67.00.

The firm’s market cap is $1.21 billion. The company has a 50 day moving average price of $40.07 and a 200-day moving average price of $34.69.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by $0.06. Equities research analysts anticipate that Sage Therapeutics Inc. will post ($4.42) earnings per share for the current year.

In related news, CFO Kimi Iguchi sold 5,000 shares of Sage Therapeutics stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $49.55, for a total transaction of $247,750.00. Following the completion of the transaction, the chief financial officer now owns 83,739 shares in the company, valued at $4,149,267.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Albert Robichaud sold 22,000 shares of Sage Therapeutics stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $40.00, for a total value of $880,000.00. Following the transaction, the insider now owns 140,222 shares of the company’s stock, valued at approximately $5,608,880. The disclosure for this sale can be found here.

A number of institutional investors have bought and sold shares of SAGE. Schwab Charles Investment Management Inc. boosted its position in Sage Therapeutics by 9.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 39,930 shares of the biopharmaceutical company’s stock worth $2,328,000 after buying an additional 3,453 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Sage Therapeutics during the fourth quarter worth about $1,870,000. RS Investment Management Co. LLC boosted its stake in shares of Sage Therapeutics by 14.7% in the fourth quarter. RS Investment Management Co. LLC now owns 504,405 shares of the biopharmaceutical company’s stock worth $29,407,000 after buying an additional 64,567 shares in the last quarter. Finally, Jennison Associates LLC purchased a new stake in shares of Sage Therapeutics during the fourth quarter worth about $14,875,000.

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.